التفاصيل البيبلوغرافية
| العنوان: |
Renoprotective Effects of Edaravone in a Model of Acute kidney Injury Induced by Rhabdomyolysis in Rats, the Involvement of Nitric oxide. |
| المؤلفون: |
Moezi, Leila, Panjehshahin, Mohammad Reza, Torabinezhad, Simin, Kamali-Sarvestani, Eskandar, Farjadian, Shirin, Pirsalami, Fatema, Ebrahimpour, Azin, Oftadehgan, Somayeh, Purkhosrow, Azar, Mojahedtaghi, Maryam, Sattarinezhad, Elahe |
| المصدر: |
Trends in Pharmaceutical Sciences; 2022, Vol. 8 Issue 2, p85-94, 10p |
| مصطلحات موضوعية: |
EDARAVONE, ACUTE kidney failure, NITRIC oxide, RHABDOMYOLYSIS, NANOTECHNOLOGY |
| مستخلص: |
Edaravone is a free radical scavenger which is used as a drug for the treatment of cerebral infarction and amyotrophic lateral sclerosis. Edaravone is distributed widely in the body and its effects are not limited to the neural tissue. Many studies indicate that edaravone has some nitric oxide synthase (NOS) modulating properties. In this research we evaluated the effects of edaravone (1, 5 and 10 mg/kg) alone or in concombination with diphenyliodonium chloride (a specific endothelial NOS inhibitor) or aminoguanidine (a specific inducible NOS inhibitor) on oxidative stress, and renal tissue and function in a model of acute kidney injury induced by a single intramuscular injection of hypertonic glycerol solution. Effects of edaravone on gene expressions of eNOS and iNOS (by RT-PCR) were also investigated. Data were analyzed using one-way analysis of variance (ANOVA) followed by Tukey's test. At the end of this study, edaravone attenuated oxidative stress and improved renal tissue damage and dysfunction. Aminoguanidine enhanced the renoprotective effects of edaravone. Edaravone showed no remarkable effect on the expression of eNOS gene but it reduced the induction of iNOS gene significantly. The results of this study showed that edaravone could protect against rhabdomyolysis-induced acute kidney injury using its antioxidant activity and inhibiting effect on iNOS gene expression. [ABSTRACT FROM AUTHOR] |
|
Copyright of Trends in Pharmaceutical Sciences is the property of Shiraz University of Medical Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder